Author/Creator: Skrivanek, Z. - British Library Electronic Legal Deposit Catalogue-Journal Issues and Articles Search Results

Author/Creator Skrivanek, Z.

1. Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once‐weekly dulaglutide AWARD programme. Issue 1 (3rd November 2015)

Authors:: Dungan, K. M.; Raz, I.; Skrivanek, Z.; Sealls, W.; Fahrbach, J. L.
Journal:: Diabetes, obesity & metabolism
Issue:: Volume 18:Issue 1(2016)
Page Start:: 49
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

2. Dose‐finding results in an adaptive, seamless, randomized trial of once‐weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD‐5). Issue 8 (22nd May 2014)

Authors:: Skrivanek, Z.; Gaydos, B. L.; Chien, J. Y.; Geiger, M. J.; Heathman, M. A.; Berry, S.; Anderson, J. H.; Forst, T.; Milicevic, Z.; Berry, D.
Journal:: Diabetes, obesity & metabolism
Issue:: Volume 16:Issue 8(2014:Aug.)
Page Start:: 748
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

3. Low incidence of anti‐drug antibodies in patients with type 2 diabetes treated with once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide. Issue 5 (4th March 2016)

Authors:: Milicevic, Z.; Anglin, G.; Harper, K.; Konrad, R. J.; Skrivanek, Z.; Glaesner, W.; Karanikas, C. A.; Mace, K.
Journal:: Diabetes, obesity & metabolism
Issue:: Volume 18:Issue 5(2016)
Page Start:: 533
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

4. Network meta‐analysis accurately predicted the outcome of a subsequent randomised trial comparing once weekly dulaglutide 1.5 mg and once daily liraglutide 1.8 mg. Issue 3 (24th February 2016)

Authors:: Fahrbach, J. L.; Fu, H.; Shurzinske, L.; Skrivanek, Z.; Martin, S.
Journal:: International journal of clinical practice
Issue:: Volume 70:Issue 3(2016)
Page Start:: 218
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

5. Safety and efficacy of once‐weekly dulaglutide versus sitagliptin after 2 years in metformin‐treated patients with type 2 diabetes (AWARD‐5): a randomized, phase III study. Issue 9 (20th May 2015)

Authors:: Weinstock, R. S.; Guerci, B.; Umpierrez, G.; Nauck, M. A.; Skrivanek, Z.; Milicevic, Z.
Journal:: Diabetes, obesity & metabolism
Issue:: Volume 17:Issue 9(2015:Sep.)
Page Start:: 849
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗